Acuta Capital Partners, LLC Viridian Therapeutics, Inc.\De Transaction History

Acuta Capital Partners, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$17.09 - $23.82 $1.4 Million - $1.95 Million	-82,067 Reduced 29.15%	199,433 $3.49 Million
Q4 2023 Feb 14, 2024	BUY	$11.12 - $22.5 $635,630 - $1.29 Million	57,161 Added 25.48%	281,500 $6.13 Million
Q3 2023 Nov 14, 2023	SELL	$15.16 - $24.7 $5,578 - $9,089	-368 Reduced 0.16%	224,339 $3.44 Million
Q2 2023 Aug 14, 2023	BUY	$22.57 - $29.67 $1.28 Million - $1.68 Million	56,707 Added 33.75%	224,707 $5.35 Million
Q1 2023 May 15, 2023	SELL	$25.04 - $37.6 $5.72 Million - $8.59 Million	-228,500 Reduced 57.63%	168,000 $4.27 Million
Q4 2022 Feb 14, 2023	BUY	$18.78 - $29.74 $634,106 - $1 Million	33,765 Added 9.31%	396,500 $11.6 Million
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $1.38 Million - $3.28 Million	128,709 Added 55.0%	362,735 $7.44 Million
Q2 2022 Aug 15, 2022	SELL	$9.55 - $19.0 $1.01 Million - $2.01 Million	-105,974 Reduced 31.17%	234,026 $2.71 Million
Q1 2022 May 16, 2022	BUY	$16.79 - $20.88 $369,380 - $459,360	22,000 Added 6.92%	340,000 $6.29 Million
Q4 2021 Feb 14, 2022	BUY	$15.65 - $21.5 $2.85 Million - $3.92 Million	182,193 Added 134.16%	318,000 $6.29 Million
Q3 2021 Nov 15, 2021	BUY	$10.69 - $18.2 $1.45 Million - $2.47 Million	135,807 New	135,807 $2.23 Million

179

76.8M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $789M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.